Do you want to read an article? Please log in or register.
Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Med.
Mondejar-Lopez P, Quintana-Gallego E, Giron-Moreno RM, Cortell-Aznar I, Ruiz de Valbuena-Maiz M, Diab-Caceres L, Prados-Sanchez C, Alvarez-Fernandez A, Garcia-Marcos PW, Peñalver-Mellado C, Pastor-Vivero MD, Olveira C, Lopez-Neyra A, Castillo-Corullon S, Palma-Milla S, Perez-Ruiz E, Sole-Jover A, Barrio MI, Sanchez-Solis M, Asensio de la Cruz Ó, CF-COVID19-Spain Registry Group
doi: 10.1016/j.rmed.2020.106062.
RECOMMENDED
Pulmonary Fibrosis
Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Wolter DJ, Onchiri FM, Emerson J, Precit MR, Lee M, McNamara S, Nay L, Blackledge M, Uluer A, Orenstein DM, Mann M, Hoover W, Gibson RL, Burns JL, Hoffman LR, SCVSA study group.
doi: 10.1016/S2213-2600(19)30365-0.Visit the original publication at ncbi.nlm.nih.gov
RECOMMENDED
Respiratory Tract Infection
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Infect Dis.
Tabata S, Imai K, Kawano S, Ikeda M, Kodama T, Miyoshi K, Obinata H, Mimura S, Kodera T, Kitagaki M, Sato M, Suzuki S, Ito T, Uwabe Y, Tamura K
doi: 10.1016/S1473-3099(20)30482-5.
RECOMMENDED
Pulmonary Fibrosis
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
McClenaghan E, Cosgriff R, Brownlee K, Ahern S, Burgel PR, Byrnes CA, Colombo C, Corvol H, Cheng SY, Daneau G, Elbert A, Faro A, Goss CH, Gulmans V, Gutierrez H, de Monestrol I, Jung A, Justus LN, Kashirskaya N, Marshall BC, McKone E, Middleton PG, Mondejar-Lopez P, Pastor-Vivero MD, Padoan R, Rizvi S, Ruseckaite R, Salvatore M, Stephenson A, Filho LVRDS, Melo J, Zampoli M, Carr SB
doi: 10.1016/j.jcf.2020.10.003
RECOMMENDED
Pulmonary Fibrosis
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros.
Cosgriff R, Ahern S, Bell SC, Brownlee K, Burgel PR, Byrnes C, Corvol H, Cheng SY, Elbert A, Faro A, Goss CH, Gulmans V, Marshall BC, McKone E, Middleton PG, Ruseckaite R, Stephenson AL, Carr SB
doi: 10.1016/j.jcf.2020.04.012.
RECOMMENDED
Pneumonia
Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Crit Care
García-Salido A, de Carlos Vicente JC, Belda Hofheinz S, Balcells Ramírez J, Slöcker Barrio M, Leóz Gordillo I, Hernández Yuste A, Guitart Pardellans C, Cuervas-Mons Tejedor M, Huidobro Labarga B, Vázquez Martínez JL, Gutiérrez Jimeno M, Oulego-Erróz I, Trastoy Quintela J, Medina Monzón C, Medina Ramos L, Holanda Peña MS, Gil-Antón J, Sorribes Ortí C, Flores González JC, Hernández Palomo RM, Sánchez Ganfornina I, Fernández Romero E, García-Besteiro M, López-Herce Cid J, González Cortés R, Spanish Pediatric Intensive Care Society working group on SARS-CoV-2 infection.
doi: 10.1186/s13054-020-03332-4
Pulmonary Fibrosis
Children with cystic fibrosis demonstrate no respiratory immunological, infective or physiological, consequences of vitamin D deficiency
J Cyst Fibros.
Thursfield RM, Naderi K, Leaver N, Rosenthal M, Alton EWFW, Bush A, Davies JC
doi: 10.1016/j.jcf.2018.02.011.
RECOMMENDED
Pulmonary Fibrosis
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
Lancet Respir Med.
McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS
doi: 10.1016/S2213-2600(18)30460-0.
RECOMMENDED
Pulmonary Fibrosis
Clinical characteristics and outcomes associated with Inquilinus infection in cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros.
Lenhart-Pendergrass PM, Caverly LJ, Wagner BD, Sagel SD, Nick JA, LiPuma JJ, Martiniano SL
doi: 10.1016/j.jcf.2020.07.011.